Oracle Recognized as a Leader in 2025 IDC MarketScape for Worldwide Life Science R&D Pharmacovigilance Technology Solutions and Consulting Services

Rhea-AI Summary

Oracle (NYSE:ORCL) has been named a leader in the 2025 IDC MarketScape for Worldwide Life Science R&D Pharmacovigilance Technology Solutions and Consulting Services. The company's pharmacovigilance (PV) division demonstrates strong market dominance with 60% market share in PV software and projects 20% annual revenue growth over the next three years.

Oracle's comprehensive ecosystem includes the Safety One Platform, Oracle Real-World Data, Health Data Intelligence platform, and Oracle Cloud Infrastructure AI Services. The company has secured 100 new PV customers in the past year and maintains over 400 direct PV customers. Notably, Oracle's Argus platform processes 70% of all drug ICSRs and 90% of vaccine ICSRs reported to the FDA since 2017.

Positive

• Dominant 60% market share in pharmacovigilance software market
• Projected 20% annual revenue growth in PV division for next 3 years
• Addition of 100 new PV customers in past 12 months
• Controls 70% of drug ICSRs and 90% of vaccine ICSRs reported to FDA
• Extensive experience with over 100,000 clinical trials with PV focus

Negative

• None.

News Market Reaction

-0.54%

1 alert

-0.54% News Effect

On the day this news was published, ORCL declined 0.54%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AUSTIN, Texas, Sept. 30, 2025 /PRNewswire/ -- Oracle has been recognized as a leader in the 2025 IDC MarketScape: Worldwide Life Science R&D Pharmacovigilance (PV) Technology Solutions and Consulting Services 2025 Vendor Assessment¹. The report notes that, "Oracle is bringing together its Safety One Platform, Oracle Real-World Data (ORWD), Health Data Intelligence (HDI) platform, and Oracle Cloud Infrastructure (OCI) Artificial Intelligence (AI) Services to drive its precision PV strategy."

"By bringing together its solutions for safety, data, and intelligence, Oracle is building a connected ecosystem for precision PV," said Dr. Nimita Limaye, research vice president, Life Sciences R&D Strategy and Technology, IDC. "This approach, combined with their regulatory expertise and extensive customer base, positions Oracle to guide the industry towards more proactive and intelligent drug safety management."

"This recognition from the IDC MarketScape further validates Oracle's pivotal role in advancing drug safety innovation and the significant investments we have made in R&D to help our customers more swiftly and safely get life-saving treatments to market," said Seema Verma, executive vice president and general manager, Oracle Health and Life Sciences. "We further believe Oracle's Safety One platform, combined with our deep domain and AI expertise, is equipping organizations to confidently navigate the complexities of modern pharmacovigilance, helping to ensure they are future-ready for evolving regulatory landscapes and safety challenges."

The report noted, "Oracle has been providing PV technology solutions and consulting services for close to three decades. It estimates that its PV revenue will grow by 20% annually in the next three years and reports that it owns close to 60% of the PV software market share. It has supported over 100,000 clinical trials, 90% of which included a PV focus. It has over 400 direct PV customers and has acquired close to 100 new customers in the past 12 months. Over 70% of all drug Individual Case Safety Reports (ICSRs) and more than 90% of all vaccine ICSRs reported to the FDA since 2017 originate in Argus."

By continuously delivering advanced, AI-powered solutions and comprehensive services, Oracle empowers its customers to optimize pharmacovigilance operations and uphold the highest standards of patient safety.

To access the 2025 IDC MarketScape for Worldwide Life Science R&D Pharmacovigilance (PV) Technology Solutions and Consulting Services excerpt visit: https://www.oracle.com/life-sciences/safety-solutions/

About IDC MarketScape
IDC MarketScape vendor assessment model is designed to provide an overview of the competitive fitness of technology and service suppliers in a given market. The research utilizes a rigorous scoring methodology based on both qualitative and quantitative criteria that results in a single graphical illustration of each supplier's position within a given market. IDC MarketScape provides a clear framework in which the product and service offerings, capabilities and strategies, and current and future market success factors of technology suppliers can be meaningfully compared. The framework also provides technology buyers with a 360-degree assessment of the strengths and weaknesses of current and prospective suppliers.

About Oracle Life Sciences
Oracle Life Sciences is a leader in cloud technology, pharmaceutical research, and consulting, trusted globally by professionals in both large and emerging companies engaged in clinical research and pharmacovigilance, throughout the therapeutic development lifecycle, including pre- and post-drug launch activities. With more than 20 years of experience, Oracle Life Sciences is committed to supporting clinical development and leveraging real-world evidence to deliver innovation and accelerate advancements--empowering the life sciences industry to improve patient outcomes. Learn more at www.oracle.com/life-sciences.

About Oracle
Oracle offers integrated suites of applications plus secure, autonomous infrastructure in the Oracle Cloud. For more information about Oracle (NYSE: ORCL), please visit us at www.oracle.com.

Trademarks
Oracle, Java, MySQL and NetSuite are registered trademarks of Oracle Corporation. NetSuite was the first cloud company--ushering in the new era of cloud computing.

¹ 2025 IDC MarketScape for Worldwide Life Science R&D Pharmacovigilance (PV) Technology Solutions and Consulting Services (doc # US53669225, July 2025) - https://www.oracle.com/life-sciences/safety-solutions/

View original content to download multimedia:https://www.prnewswire.com/news-releases/oracle-recognized-as-a-leader-in-2025-idc-marketscape-for-worldwide-life-science-rd-pharmacovigilance-technology-solutions-and-consulting-services-302569964.html

SOURCE Oracle

FAQ

What is Oracle's market share in the pharmacovigilance software market?

Oracle owns approximately 60% of the pharmacovigilance software market share and processes over 70% of drug ICSRs and 90% of vaccine ICSRs reported to the FDA since 2017.

How many new pharmacovigilance customers did Oracle acquire in 2025?

Oracle has acquired approximately 100 new pharmacovigilance customers in the past 12 months, adding to their existing base of over 400 direct PV customers.

What is Oracle's projected growth rate for their pharmacovigilance revenue?

Oracle estimates that its pharmacovigilance revenue will grow by 20% annually over the next three years.

What key technologies does Oracle use for pharmacovigilance?

Oracle utilizes its Safety One Platform, Oracle Real-World Data (ORWD), Health Data Intelligence (HDI) platform, and Oracle Cloud Infrastructure (OCI) AI Services for its precision pharmacovigilance strategy.

How many clinical trials has Oracle supported with pharmacovigilance focus?

Oracle has supported over 100,000 clinical trials, with 90% of them including a pharmacovigilance focus.